依那西普 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "依那西普" in Chinese language version.

refsWebsite

Global rank Chinese rank

42web.archive.org

1^st place

14nih.gov

4^th place

5^th place

12doi.org

2^nd place

23^rd place

8fda.gov

447^th place

581^st place

7europa.eu

68^th place

209^th place

3medicines.org.uk

3,823^rd place

3,456^th place

3semanticscholar.org

11^th place

332^nd place

2funnelback.com

low place

2tga.gov.au

3,984^th place

1,603^rd place

2gabionline.net

low place

2duke.edu

1,880^th place

2,453^rd place

1drugs.com

399^th place

208^th place

1hres.ca

low place

1dukemednews.org

low place

1archive.org

6^th place

4^th place

1handle.net

102^nd place

492^nd place

1springer.com

274^th place

320^th place

1espacenet.com

800^th place

1,214^th place

1abovethelaw.com

low place

1aan.com

low place

6,643^rd place

1cnn.com

28^th place

71^st place

1harvard.edu

18^th place

57^th place

1biopharmadive.com

low place

5,099^th place

1sskrplaw.com

low place

1seattletimes.com

519^th place

1,496^th place

1nytimes.com

7^th place

31^st place

1bostonherald.com

1,644^th place

4,405^th place

1archive.today

14^th place

18^th place

1squarespace.com

2,953^rd place

7,308^th place

1sec.gov

572^nd place

452^nd place

1uspto.gov

1,459^th place

1,685^th place

1spglobal.com

4,563^rd place

3,308^th place

aan.com

Practice Advisory: Etanercept for Poststroke Disability (pdf). American Academy of Neurology. 2016-06-06 [2024-01-11]. （原始内容存档于2023-01-08）.

abovethelaw.com

Another Free Speech Win In Libel Lawsuit Disguised As A Trademark Complaint. Above the Law. 2017-02-24 [2022-06-27]. （原始内容存档于2023-08-31）（美国英语）.

archive.org

Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology. June 2007, 46 (6): 999–1004. PMID 17389658. doi:10.1093/rheumatology/kem069 .

archive.today

"Co-pay hike a painful reality; Miracle drug monthly cost jumps from $42 to $600" Archive.is的存檔，存档日期2013-01-18, Margery Eagan, Boston Herald, 2011-11-03

biopharmadive.com

Gardner J. A three-decade monopoly: How Amgen built a patent thicket around its top-selling drug. 2021-11-01 [2024-01-11]. （原始内容存档于2024-06-03）.

bostonherald.com

"Co-pay hike a painful reality; Miracle drug monthly cost jumps from $42 to $600" Archive.is的存檔，存档日期2013-01-18, Margery Eagan, Boston Herald, 2011-11-03

cnn.com

money.cnn.com

Wyeth and Amgen heighten warning of life-threatening infections on skin drug Enbrel. [2008-05-02]. （原始内容存档于2008-05-05）.

doi.org

Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine. October 2003, 9 (10): 1245–1250. PMID 14520364. S2CID 52860838. doi:10.1038/nm939.
Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. The Journal of Experimental Medicine. December 1991, 174 (6): 1483–1489. PMC 2119031 . PMID 1660525. doi:10.1084/jem.174.6.1483.
Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B. Expression of a TNF inhibitor in transgenic mice. Journal of Immunology. November 1993, 151 (10): 5699–5703. PMID 7693816. S2CID 10859938. doi:10.4049/jimmunol.151.10.5699.
Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology. June 2007, 46 (6): 999–1004. PMID 17389658. doi:10.1093/rheumatology/kem069 .
Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane Database of Systematic Reviews. April 2015, 4 (4): CD005468. PMID 25887212. doi:10.1002/14651858.CD005468.pub2.
Kim PJ, Lansang RP, Vender R. A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. Journal of Cutaneous Medicine and Surgery. July 2023, 27 (4): 358–367. PMC 10486173 . PMID 37533141. doi:10.1177/12034754231188444.
Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. Journal of Immunology. August 2007, 179 (3): 1872–1883. PMID 17641054. doi:10.4049/jimmunol.179.3.1872 .
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. Journal of Clinical Oncology. September 2005, 23 (25): 5950–5959. PMID 16135466. doi:10.1200/JCO.2005.04.127.
Houel S, Hilliard M, Yu YQ, McLoughlin N, Martin SM, Rudd PM, et al. N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality. Analytical Chemistry. January 2014, 86 (1): 576–584. PMID 24308717. doi:10.1021/ac402726h.
Mukai Y, Nakamura T, Yoshikawa M, Yoshioka Y, Tsunoda S, Nakagawa S, et al. Solution of the structure of the TNF-TNFR2 complex. Science Signaling. November 2010, 3 (148): ra83. PMID 21081755. S2CID 24226117. doi:10.1126/scisignal.2000954.
Lamanna WC, Mayer RE, Rupprechter A, Fuchs M, Higel F, Fritsch C, et al. The structure-function relationship of disulfide bonds in etanercept. Scientific Reports. June 2017, 7 (1): 3951. Bibcode:2017NatSR...7.3951L. PMC 5479810 . PMID 28638112. doi:10.1038/s41598-017-04320-5.
Norman P. Enbrel and etanercept biosimilars: a tale of two patent systems. Pharmaceutical Patent Analyst. January 2017, 6 (1): 5–7. PMID 28201948. doi:10.4155/ppa-2016-0043.

drugs.com

Etanercept Use During Pregnancy. Drugs.com. 2020-01-24 [2020-08-13]. （原始内容存档于2021-01-20）.

duke.edu

scholarship.law.duke.edu

Kaldre I. The Future of Generic Biologics: Should the United States "Follow-On" the European Pathway?. www.law.duke.edu. 2008 [2019-06-05]. （原始内容存档于2021-08-28）.
Kaldre I. The Future of Generic Biologics: Should the United States "Follow-On" the European Pathway?. www.law.duke.edu. 2008 [2019-06-05]. （原始内容存档于2021-08-28）.

dukemednews.org

Arthritis Drug Effective for Depression in Psoriasis Sufferers. [2008-01-10]. （原始内容存档于2007-10-20）.

espacenet.com

worldwide.espacenet.com

US 8900583,Tobinick EL,「Methods for treatment of brain injury utilizing biologics」,发表于2014-12-02

europa.eu

ema.europa.eu

Nepexto EPAR. European Medicines Agency. 24 March 2020 [2023-03-04]. （原始内容存档于2020-06-04）.
Enbrel EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-02]. （原始内容存档于2020-11-12）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Benepali EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-02]. （原始内容存档于2019-12-30）.
Lifmior EPAR. European Medicines Agency (EMA). 2018-09-17 [2 April 2020]. （原始内容存档于2020-11-29）.
Public statement on Lifmior: Withdrawal of the marketing authorisation in the European Union (PDF). [2020-04-02]. （原始内容存档 (PDF)于2021-08-28）.
Erelzi EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-02]. （原始内容存档于2019-12-30）.

ec.europa.eu

Nepexto Product information. Union Register of medicinal products. [2023-03-03]. （原始内容存档于2023-03-05）.

fda.gov

accessdata.fda.gov

Drugs@FDA: FDA-Approved Drugs. [2024-01-11]. （原始内容存档于2024-04-18）.
Approval of Etanercept for treatment of psoriatic arthritis (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 2002-01-15 [2015-04-14]. （原始内容存档于2021-01-22）.
Approval of Etanercept for treatment of ankylosing spondylitis (PDF) (Letter). Letter to Douglas Hunt. U.S. Food and Drug Administration (FDA). 2003-07-24 [2015-04-14]. （原始内容存档 (PDF)于2021-01-22）.
Approval of Etanercept for treatment of moderate to severe plaque psoriasis (PDF) (Letter). Letter to Douglas Hunt. U.S. Food and Drug Administration (FDA). 2004-04-30 [2015-04-14]. （原始内容存档 (PDF)于2021-01-06）.

fda.gov

Approval of Etanercept for treatment of rheumatoid arthritis (PDF) (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 1998-11-02 [2015-04-14]. （原始内容存档 (PDF)于2015-09-24）.
Approval of Etanercept for treatment of polyarticular course juvenile rheumatoid arthritis (JRA) (PDF) (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 1999-05-27 [2015-04-14]. （原始内容存档 (PDF)于2015-09-24）.
Safety Update on TNF- α Antagonists: Infliximab and Etanercept (PDF). U.S. Food and Drug Administration (FDA): 13–14. [2013-12-20]. （原始内容 (PDF)存档于2015-09-24）.
Etanercept Product Approval Information - Licensing Action 12/2/98. U.S. Food and Drug Administration (FDA). 2016-04-01 [2020-06-04]. （原始内容存档于2017-01-18）.

funnelback.com

tga-search.clients.funnelback.com

Etera ARTG. Therapeutic Goods Administration (TGA). [2021-06-12]. （原始内容存档于2021-06-13）.
Rymti ARTG. Therapeutic Goods Administration (TGA). [2021-06-12]. （原始内容存档于2021-06-13）.

gabionline.net

New Amgen Enbrel patent could block biosimilars until 2028. 2011-11-25 [2019-07-14]. （原始内容存档于2019-07-14）.
Japanese approval for Lupin's etanercept biosimilar. [2024-01-11]. （原始内容存档于2023-12-28）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Lamanna WC, Mayer RE, Rupprechter A, Fuchs M, Higel F, Fritsch C, et al. The structure-function relationship of disulfide bonds in etanercept. Scientific Reports. June 2017, 7 (1): 3951. Bibcode:2017NatSR...7.3951L. PMC 5479810 . PMID 28638112. doi:10.1038/s41598-017-04320-5.

hres.ca

hpr-rps.hres.ca

Rymti Summary Basis of Decision. Health Canada. 2014-10-23 [2023-03-10]. （原始内容存档于2023-05-27）.

medicines.org.uk

Benepali 25 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC). (emc). 2021-01-25 [2021-06-12]. （原始内容存档于2023-12-28）.
Enbrel 25mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). (emc). 2021 -06-08 [2021-06-12]. （原始内容存档于2023-12-28）. 请检查|date=中的日期值 (帮助)
Erelzi 50 mg solution for injection in pre filled pen - Summary of Product Characteristics (SmPC). (emc). 2021-05-25 [2021-06-12]. （原始内容存档于2024-02-27）.

nih.gov

ncbi.nlm.nih.gov

Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine. October 2003, 9 (10): 1245–1250. PMID 14520364. S2CID 52860838. doi:10.1038/nm939.
Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. The Journal of Experimental Medicine. December 1991, 174 (6): 1483–1489. PMC 2119031 . PMID 1660525. doi:10.1084/jem.174.6.1483.
Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B. Expression of a TNF inhibitor in transgenic mice. Journal of Immunology. November 1993, 151 (10): 5699–5703. PMID 7693816. S2CID 10859938. doi:10.4049/jimmunol.151.10.5699.
Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology. June 2007, 46 (6): 999–1004. PMID 17389658. doi:10.1093/rheumatology/kem069 .
Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane Database of Systematic Reviews. April 2015, 4 (4): CD005468. PMID 25887212. doi:10.1002/14651858.CD005468.pub2.
Kim PJ, Lansang RP, Vender R. A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. Journal of Cutaneous Medicine and Surgery. July 2023, 27 (4): 358–367. PMC 10486173 . PMID 37533141. doi:10.1177/12034754231188444.
Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. Journal of Immunology. August 2007, 179 (3): 1872–1883. PMID 17641054. doi:10.4049/jimmunol.179.3.1872 .
Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. Journal of Clinical Oncology. September 2005, 23 (25): 5950–5959. PMID 16135466. doi:10.1200/JCO.2005.04.127.
Smola MG, Soyer HP, Scharnagl E. Surgical treatment of dermatofibrosarcoma protuberans. A retrospective study of 20 cases with review of literature. European Journal of Surgical Oncology. October 1991, 17 (5): 447–453. PMID 1936291.
Houel S, Hilliard M, Yu YQ, McLoughlin N, Martin SM, Rudd PM, et al. N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality. Analytical Chemistry. January 2014, 86 (1): 576–584. PMID 24308717. doi:10.1021/ac402726h.
Mukai Y, Nakamura T, Yoshikawa M, Yoshioka Y, Tsunoda S, Nakagawa S, et al. Solution of the structure of the TNF-TNFR2 complex. Science Signaling. November 2010, 3 (148): ra83. PMID 21081755. S2CID 24226117. doi:10.1126/scisignal.2000954.
Lamanna WC, Mayer RE, Rupprechter A, Fuchs M, Higel F, Fritsch C, et al. The structure-function relationship of disulfide bonds in etanercept. Scientific Reports. June 2017, 7 (1): 3951. Bibcode:2017NatSR...7.3951L. PMC 5479810 . PMID 28638112. doi:10.1038/s41598-017-04320-5.
Norman P. Enbrel and etanercept biosimilars: a tale of two patent systems. Pharmaceutical Patent Analyst. January 2017, 6 (1): 5–7. PMID 28201948. doi:10.4155/ppa-2016-0043.

dailymed.nlm.nih.gov

Enbrel- etanercept solution Enbrel- etanercept kit. DailyMed. [2021-04-17]. （原始内容存档于2024-02-28）.

nytimes.com

Pollock A. Amgen's New Enbrel Patent May Undercut Health Care Plan. The New York Times. 2011-11-23 [2023-03-10]. （原始内容存档于2021-07-25）.

seattletimes.com

"What's behind the whopping price tags on the newest generation of drugs: （页面存档备份，存于互联网档案馆） The story behind the production of Enbrel, Amgen's popular rheumatoid arthritis drug, provides insights as to why bioengineered drugs are so expensive." Carol M. Ostrom, Seattle Times, 2008-08-18

sec.gov

Portions of the 2010 Financial Report. Sec.gov. [2019-06-05]. （原始内容存档于2019-06-10）.

semanticscholar.org

api.semanticscholar.org

Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine. October 2003, 9 (10): 1245–1250. PMID 14520364. S2CID 52860838. doi:10.1038/nm939.
Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B. Expression of a TNF inhibitor in transgenic mice. Journal of Immunology. November 1993, 151 (10): 5699–5703. PMID 7693816. S2CID 10859938. doi:10.4049/jimmunol.151.10.5699.
Mukai Y, Nakamura T, Yoshikawa M, Yoshioka Y, Tsunoda S, Nakagawa S, et al. Solution of the structure of the TNF-TNFR2 complex. Science Signaling. November 2010, 3 (148): ra83. PMID 21081755. S2CID 24226117. doi:10.1126/scisignal.2000954.

spglobal.com

Indian firm Cipla has announced the launch of its etanercept product in India.. S&P Global Market Intelligence. 2013-04-18 [2023-12-28]. （原始内容存档于2023-12-28）.

springer.com

New hope for survivors of stroke and traumatic brain injury. Springer Select. 2012-10-31 [2018-11-17]. （原始内容存档于2021-06-25）.

squarespace.com

static1.squarespace.com

2013 Comparative Price Report (PDF). International Federation of Health Plans. [2017-11-24]. （原始内容 (PDF)存档于2017-10-22）.

sskrplaw.com

Kowalczyk L. Lucrative Licensing Deals With Drug, Biotech Firms Are Raising Ethics Issues For Hospitals. 2002-03-24 [2024-01-11]. （原始内容存档于2023-10-02）.

tga.gov.au

Australian Public Assessment Report for Etanercept (PDF). Feb 2021 [2024-01-11]. （原始内容存档 (PDF)于2024-01-14）.
AusPAR: Etanercept. Therapeutic Goods Administration (TGA). 2021-02-25 [2021-06-12]. （原始内容存档于2021-06-13）.

uspto.gov

Patent Terms Extended Under 35 USC §156. [2009-12-09]. （原始内容存档于2010-02-24）.

web.archive.org

Etera ARTG. Therapeutic Goods Administration (TGA). [2021-06-12]. （原始内容存档于2021-06-13）.
Nepexto EPAR. European Medicines Agency. 24 March 2020 [2023-03-04]. （原始内容存档于2020-06-04）.
Rymti ARTG. Therapeutic Goods Administration (TGA). [2021-06-12]. （原始内容存档于2021-06-13）.
Australian Public Assessment Report for Etanercept (PDF). Feb 2021 [2024-01-11]. （原始内容存档 (PDF)于2024-01-14）.
Etanercept Use During Pregnancy. Drugs.com. 2020-01-24 [2020-08-13]. （原始内容存档于2021-01-20）.
Rymti Summary Basis of Decision. Health Canada. 2014-10-23 [2023-03-10]. （原始内容存档于2023-05-27）.
Benepali 25 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC). (emc). 2021-01-25 [2021-06-12]. （原始内容存档于2023-12-28）.
Enbrel 25mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). (emc). 2021 -06-08 [2021-06-12]. （原始内容存档于2023-12-28）. 请检查|date=中的日期值 (帮助)
Erelzi 50 mg solution for injection in pre filled pen - Summary of Product Characteristics (SmPC). (emc). 2021-05-25 [2021-06-12]. （原始内容存档于2024-02-27）.
Enbrel- etanercept solution Enbrel- etanercept kit. DailyMed. [2021-04-17]. （原始内容存档于2024-02-28）.
Enbrel EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-02]. （原始内容存档于2020-11-12）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Nepexto Product information. Union Register of medicinal products. [2023-03-03]. （原始内容存档于2023-03-05）.
Drugs@FDA: FDA-Approved Drugs. [2024-01-11]. （原始内容存档于2024-04-18）.
Arthritis Drug Effective for Depression in Psoriasis Sufferers. [2008-01-10]. （原始内容存档于2007-10-20）.
Approval of Etanercept for treatment of rheumatoid arthritis (PDF) (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 1998-11-02 [2015-04-14]. （原始内容存档 (PDF)于2015-09-24）.
Approval of Etanercept for treatment of polyarticular course juvenile rheumatoid arthritis (JRA) (PDF) (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 1999-05-27 [2015-04-14]. （原始内容存档 (PDF)于2015-09-24）.
Approval of Etanercept for treatment of psoriatic arthritis (Letter). Letter to Sally Gould. U.S. Food and Drug Administration (FDA). 2002-01-15 [2015-04-14]. （原始内容存档于2021-01-22）.
Approval of Etanercept for treatment of ankylosing spondylitis (PDF) (Letter). Letter to Douglas Hunt. U.S. Food and Drug Administration (FDA). 2003-07-24 [2015-04-14]. （原始内容存档 (PDF)于2021-01-22）.
Approval of Etanercept for treatment of moderate to severe plaque psoriasis (PDF) (Letter). Letter to Douglas Hunt. U.S. Food and Drug Administration (FDA). 2004-04-30 [2015-04-14]. （原始内容存档 (PDF)于2021-01-06）.
New hope for survivors of stroke and traumatic brain injury. Springer Select. 2012-10-31 [2018-11-17]. （原始内容存档于2021-06-25）.
Another Free Speech Win In Libel Lawsuit Disguised As A Trademark Complaint. Above the Law. 2017-02-24 [2022-06-27]. （原始内容存档于2023-08-31）（美国英语）.
Practice Advisory: Etanercept for Poststroke Disability (pdf). American Academy of Neurology. 2016-06-06 [2024-01-11]. （原始内容存档于2023-01-08）.
Wyeth and Amgen heighten warning of life-threatening infections on skin drug Enbrel. [2008-05-02]. （原始内容存档于2008-05-05）.
Safety Update on TNF- α Antagonists: Infliximab and Etanercept (PDF). U.S. Food and Drug Administration (FDA): 13–14. [2013-12-20]. （原始内容 (PDF)存档于2015-09-24）.
Gardner J. A three-decade monopoly: How Amgen built a patent thicket around its top-selling drug. 2021-11-01 [2024-01-11]. （原始内容存档于2024-06-03）.
Kowalczyk L. Lucrative Licensing Deals With Drug, Biotech Firms Are Raising Ethics Issues For Hospitals. 2002-03-24 [2024-01-11]. （原始内容存档于2023-10-02）.
Etanercept Product Approval Information - Licensing Action 12/2/98. U.S. Food and Drug Administration (FDA). 2016-04-01 [2020-06-04]. （原始内容存档于2017-01-18）.
"What's behind the whopping price tags on the newest generation of drugs: （页面存档备份，存于互联网档案馆） The story behind the production of Enbrel, Amgen's popular rheumatoid arthritis drug, provides insights as to why bioengineered drugs are so expensive." Carol M. Ostrom, Seattle Times, 2008-08-18
Pollock A. Amgen's New Enbrel Patent May Undercut Health Care Plan. The New York Times. 2011-11-23 [2023-03-10]. （原始内容存档于2021-07-25）.
2013 Comparative Price Report (PDF). International Federation of Health Plans. [2017-11-24]. （原始内容 (PDF)存档于2017-10-22）.
Portions of the 2010 Financial Report. Sec.gov. [2019-06-05]. （原始内容存档于2019-06-10）.
Patent Terms Extended Under 35 USC §156. [2009-12-09]. （原始内容存档于2010-02-24）.
New Amgen Enbrel patent could block biosimilars until 2028. 2011-11-25 [2019-07-14]. （原始内容存档于2019-07-14）.
Kaldre I. The Future of Generic Biologics: Should the United States "Follow-On" the European Pathway?. www.law.duke.edu. 2008 [2019-06-05]. （原始内容存档于2021-08-28）.
Kaldre I. The Future of Generic Biologics: Should the United States "Follow-On" the European Pathway?. www.law.duke.edu. 2008 [2019-06-05]. （原始内容存档于2021-08-28）.
Indian firm Cipla has announced the launch of its etanercept product in India.. S&P Global Market Intelligence. 2013-04-18 [2023-12-28]. （原始内容存档于2023-12-28）.
Benepali EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-02]. （原始内容存档于2019-12-30）.
Lifmior EPAR. European Medicines Agency (EMA). 2018-09-17 [2 April 2020]. （原始内容存档于2020-11-29）.
Public statement on Lifmior: Withdrawal of the marketing authorisation in the European Union (PDF). [2020-04-02]. （原始内容存档 (PDF)于2021-08-28）.
Erelzi EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-02]. （原始内容存档于2019-12-30）.
Japanese approval for Lupin's etanercept biosimilar. [2024-01-11]. （原始内容存档于2023-12-28）.
AusPAR: Etanercept. Therapeutic Goods Administration (TGA). 2021-02-25 [2021-06-12]. （原始内容存档于2021-06-13）.